Original ArticleDetermination and characterization of process impurities for EPROSARTAN (cas 133040-01-4) mesylate
-
Add time:09/09/2019 Source:sciencedirect.com
AimThe present work aim to develop a novel, sensitive and selective HPLC method for the determination of process impurities of Eprosartan mesylate Drug substance (EPM) and characterization of impurities using Mass Spectrometry and NMR.
We also recommend Trading Suppliers and Manufacturers of EPROSARTAN (cas 133040-01-4). Pls Click Website Link as below: cas 133040-01-4 suppliers
Prev:Risk assessment and QbD based optimization of an EPROSARTAN (cas 133040-01-4) mesylate nanosuspension: In-vitro characterization, PAMPA and in-vivo assessment
Next:Enhanced dissolution/caco-2 permeability, pharmacokinetic and pharmacodynamic performance of re-dispersible EPROSARTAN (cas 133040-01-4) mesylate nanopowder) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Enhanced dissolution/caco-2 permeability, pharmacokinetic and pharmacodynamic performance of re-dispersible EPROSARTAN (cas 133040-01-4) mesylate nanopowder09/10/2019
- Risk assessment and QbD based optimization of an EPROSARTAN (cas 133040-01-4) mesylate nanosuspension: In-vitro characterization, PAMPA and in-vivo assessment09/08/2019
- Original articleEffectiveness of EPROSARTAN (cas 133040-01-4) in diabetic hypertensive patients09/07/2019
- Pulmonary, gastrointestinal and urogenital pharmacologyAmeliorative effect of EPROSARTAN (cas 133040-01-4) on high-fat diet/streptozotocin-induced early diabetic nephropathy in rats09/06/2019
- Original articleFormulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of EPROSARTAN (cas 133040-01-4) mesylate09/05/2019
- Spectroscopic and molecular docking studies of the binding of the angiotensin II receptor blockers (ARBs) azilsartan, EPROSARTAN (cas 133040-01-4) and olmesartan to bovine serum albumin09/04/2019
- EPROSARTAN (cas 133040-01-4) mesylate loaded bilosomes as potential nano-carriers against diabetic nephropathy in streptozotocin-induced diabetic rats09/03/2019
- Original research articleOATP and MRP2-mediated hepatic uptake and biliary excretion of EPROSARTAN (cas 133040-01-4) in rat and human09/02/2019
